米国の液体塞栓剤の市場規模、シェア、動向分析レポート：製品別、用途別、最終用途別、セグメント別予測、2025年～2033年

米国の液体塞栓剤市場のサマリー

米国の液体塞栓剤の市場規模は2024年に6,697万米ドルと推計され、2033年には1億4,685万米ドルに達すると予測され、2025年から2033年までのCAGRは9.26%で成長します。この成長は、技術の進歩、血管障害の有病率の増加、低侵襲手技への嗜好の高まり、塞栓剤材料の進歩、応用分野の拡大によってもたらされます。

動脈瘤、動静脈奇形（AVM）、多血管腫瘍などの神経血管や末梢血管疾患の罹患率の増加は、効果的な塞栓ソリューションへの需要を高め、市場拡大に拍車をかけています。これらの疾患では、異常な血管を塞いだり、破裂を防いだり、腫瘍への血液供給を減らしたりするために、低侵襲な処置が必要となることが多いです。液体塞栓剤は、複雑な血管構造を正確に狙い撃ちし、副次的損傷を最小限に抑えながら効果的な血管除去を行うため、こうした治療に特に適しています。

これらの疾患に対する認識が高まり、診断技術が向上するにつれて、早期に診断され塞栓療法を必要とする患者が増加しています。さらに、n-ブチルシアノアクリレート（n-BCA）やエチレンビニルアルコール共重合体（EVOH）のような塞栓材料の進歩は、これらの手技の安全性と有効性を高め、臨床医にとってより魅力的な選択肢となっています。血管内治療手技の採用拡大が、液体塞栓剤の利用をさらに後押ししています。その結果、神経血管や末梢血管の症例の急増、技術の進歩、臨床的受容の拡大が市場の拡大に拍車をかけています。例えば、2025年7月、Medtronic社はPeripheral Onyx Liquid Embolic（PELE）臨床試験における最初の患者の登録を発表しました。この試験は、末梢血管における動脈出血の塞栓に対するオニキス液体塞栓システム（LES）の安全性と有効性を評価することを目的としています。

液体塞栓剤は、動静脈奇形（AVM）、多血性腫瘍、末梢出血、その他の血管異常など様々な疾患の治療に広く使用されています。脳卒中、がん、外傷の増加により、国内では効果的な塞栓療法の需要が高まっています。例えば、Barrow Neurological Instituteによると、約30万人のアメリカ人が脳や脊髄のAVM（神経AVM）に罹患しているが、罹患者のうち症状を経験しているのは約12％に過ぎないです。

米国で事業を展開し、米国FDA認可製品を有する主要企業には、メドトロニック、セレノバス（ジョンソン・エンド・ジョンソン）、ボストンサイエンティフィックコーポレーション、テルモ、サーテックス（ブラックスワン・バスキュラー社）などがあります。さらに、シアノアクリレート系、非粘着性、エチレンビニルアルコール共重合体などの先進的な塞栓材料の採用により、治療成績と安全性が向上し、市場拡大に拍車をかけています。

外来手術の動向も市場成長に寄与しており、外来手術センターでは費用対効果と患者の利便性から塞栓術の採用が増加しています。2022年4月にInterventional Neuroradiology誌に掲載された調査論文によると、米国の病院では術前血行再建を促進するために、シアノアクリル酸n-ブチル（n-BCA）やエチレンビニルアルコール共重合体（EVOH）などの液体塞栓システム（LES）が脳動静脈奇形（bAVM）の塞栓術に利用されています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 米国の液体塞栓剤市場の変数、動向、および範囲

• 市場系統の見通し
  • 補助市場の見通し
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
  • 市場機会分析
  • 市場課題分析
• 米国液状塞栓剤市場分析ツール
  • 業界分析- ポーターのファイブフォース分析
  • PESTEL分析

第4章 米国の液体塞栓剤市場：製品別の推定・動向分析

• セグメントダッシュボード
• 米国の液状塞栓剤市場の変動分析：製品別
• 米国の液状塞栓剤市場の規模と動向分析：製品別、2021年～2033年
• エチレンビニルアルコール共重合体（EVOH）
• シアノアクリレート
  • N-BCA
  • N-HCA
• その他

第5章 米国の液体塞栓剤市場：用途別おn推定・動向分析

• セグメントダッシュボード
• 米国の液状塞栓剤市場の変動分析：用途別
• 米国の液状塞栓剤市場の規模と動向分析：用途別、2021年～2033年
• 動静脈奇形（AVM）
• 多血性腫瘍
• 末梢血管出血
• その他

第6章 米国の液体塞栓剤市場：最終用途別の推定・動向分析

• セグメントダッシュボード
• 米国の液状塞栓剤市場の変動分析：最終用途別
• 米国の液状塞栓剤市場の規模と動向分析：最終用途別、2021年～2033年
• 病院
• 専門クリニック
• 外来手術センター
• その他

第7章 競合情勢

• 市場参入企業の分類
• 主要企業プロファイル
  • Medtronic
  • Terumo
  • Boston Scientific Corporation
  • Johnson &Johnson
  • Sirtex（BlackSwan Vascular, Inc.）
  • Others
• 企業市場シェア分析、2024年
• その他の主要市場企業のリスト

List of Tables

• Table 1. List of Secondary Sources
• Table 2. List of Abbreviations
• Table 3. U.S. Liquid Embolic Agent Market, by Product, 2021 - 2033 (USD Million)
• Table 4. U.S. Liquid Embolic Agent Market, by Application, 2021 - 2033 (USD Million)
• Table 5. U.S. Liquid Embolic Agent Market, by End Use, 2021 - 2033 (USD Million)
• Table 6. Participant's Overview
• Table 7. Financial Performance
• Table 8. Product Benchmarking
• Table 9. Strategic Initiatives

List of Figures

• Fig. 1 Information Procurement
• Fig. 2 Primary Research Pattern
• Fig. 3 Market Research Approaches
• Fig. 4 Value Chain-Based Sizing & Forecasting
• Fig. 5 Market Formulation & Validation
• Fig. 6 U.S. Liquid Embolic Agent Market, Market Segmentation
• Fig. 7 Market Driver Analysis (Current & Future Impact)
• Fig. 8 Market Restraint Analysis (Current & Future Impact)
• Fig. 9 Market Opportunity Analysis (Current & Future Impact)
• Fig. 10 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
• Fig. 11 Porter's Five Forces Analysis
• Fig. 12 Regional Marketplace: Key Takeaways
• Fig. 13 U.S. Liquid Embolic Agent Market, for Product, 2021 - 2033 (USD Million)
• Fig. 14 U.S. Liquid Embolic Agent Market, for Ethylene Vinyl Alcohol Copolymer (EVOH), 2021 - 2033 (USD Million)
• Fig. 15 U.S. Liquid Embolic Agent Market, for Cyanoacrylates, 2021 - 2033 (USD Million)
• Fig. 16 U.S. Liquid Embolic Agent Market, for N-BCA, 2021 - 2033 (USD Million)
• Fig. 17 U.S. Liquid Embolic Agent Market, for N-HCA, 2021 - 2033 (USD Million)
• Fig. 18 U.S. Liquid Embolic Agent Market, for Others, 2021 - 2033 (USD Million)
• Fig. 19 U.S. Liquid Embolic Agent Market, for Arteriovenous Malformations (AVM), 2021 - 2033 (USD Million)
• Fig. 20 U.S. Liquid Embolic Agent Market, for Hypervascular Tumors, 2021 - 2033 (USD Million)
• Fig. 21 U.S. Liquid Embolic Agent Market, for Peripheral Vasculature Hemorrhage, 2021 - 2033 (USD Million)
• Fig. 22 U.S. Liquid Embolic Agent Market, for Others, 2021 - 2033 (USD Million)
• Fig. 23 U.S. Liquid Embolic Agent Market, for End Use, 2021 - 2033 (USD Million)
• Fig. 24 U.S. Liquid Embolic Agent Market, for Hospitals, 2021 - 2033 (USD Million)
• Fig. 25 U.S. Liquid Embolic Agent Market, for Specialty Clinics, 2021 - 2033 (USD Million)
• Fig. 26 U.S. Liquid Embolic Agent Market, for Ambulatory Surgery Centers, 2021 - 2033 (USD Million)
• Fig. 27 U.S. Liquid Embolic Agent Market, for Other End Use, 2021 - 2033 (USD Million)

U.S. Liquid Embolic Agent Market Summary

The U.S. liquid embolic agent market size was estimated at USD 66.97 million in 2024 and is projected to reach USD 146.85 million by 2033, growing at a CAGR of 9.26% from 2025 to 2033. This growth is driven by technological advancements, increasing prevalence of vascular disorders, rising preference for minimally invasive procedures, advancements in embolic agent materials, and expanding application areas.

The increasing incidence of neurovascular and peripheral vascular conditions such as aneurysms, arteriovenous malformations (AVMs), and hypervascular tumors has increased demand for effective embolization solutions, fueling market expansion. These conditions often require minimally invasive procedures to block abnormal blood vessels, prevent rupture, or reduce tumor blood supply. Liquid embolic agents are particularly well-suited for these treatments because they precisely target complex vascular structures, providing effective devascularization with minimal collateral damage.

As awareness of these conditions increases and diagnostic techniques improve, more patients are diagnosed early and require embolization therapy. In addition, advancements in embolic materials, such as n-butyl cyanoacrylate (n-BCA) and ethylene vinyl alcohol copolymer (EVOH), have enhanced the safety and efficacy of these procedures, making them more attractive options for clinicians. The expanding adoption of endovascular techniques further boosts the utilization of liquid embolic agents. Consequently, this surge in neurovascular and peripheral vascular condition cases, technological progress, and growing clinical acceptance fuel market expansion. For instance, in July 2025, Medtronic announced the enrollment of the first patient in the Peripheral Onyx Liquid Embolic (PELE) clinical trial. This study aims to assess the safety and efficacy of the Onyx Liquid Embolic System (LES) for the embolization of arterial hemorrhages in the peripheral vasculature.

Liquid embolic agents are widely used in the treatment of various conditions such as arteriovenous malformations (AVMs), hypervascular tumors, peripheral hemorrhages, and other vascular anomalies. The growing incidence of stroke, cancer, and traumatic injuries has increased demand for effective embolization therapies in the country. For instance, according to Barrow Neurological Institute, approximately 300,000 Americans are affected by AVMs of the brain and spinal cord (neurological AVMs), but only around 12 percent of those affected experience symptoms.

Some of the key players operating in the U.S. and having U.S. FDA-approved products include Medtronic, CERENOVUS (Johnson & Johnson), Boston Scientific Corporation, Terumo, and Sirtex (BlackSwan Vascular, Inc.). Furthermore, the adoption of advanced embolic materials, including cyanoacrylate-based, non-adhesive, and ethylene vinyl alcohol copolymer agents, has improved procedural outcomes and safety profiles, fueling market expansion.

The trend toward outpatient procedures is also contributing to market growth, with ambulatory surgical centers increasingly adopting embolization techniques due to their cost-effectiveness and patient convenience. According to a research article published in the Interventional Neuroradiology journal in April 2022, liquid embolic systems (LESs) such as n-butyl cyanoacrylate (n-BCA) and ethylene vinyl alcohol copolymer (EVOH) are utilized for the embolization of brain arteriovenous malformations (bAVMs) to facilitate presurgical devascularization in U.S. hospitals.

U.S. Liquid Embolic Agent Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. liquid embolic agent market report based on product, application, and end use:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Ethylene Vinyl Alcohol Copolymer (EVOH)
• Cyanoacrylates
  • N-BCA
  • N-HCA
• Others
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Arteriovenous Malformations (AVM)
• Hypervascular Tumors
• Peripheral Vasculature Hemorrhage
• Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals
• Specialty Clinics
• Ambulatory Surgery Centers
• Other End Use

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Application
  • 1.2.3. End Use
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
  • 1.5.5. Information Analysis
  • 1.5.6. Data Analysis Models
• 1.6. Market Formulation & Data Visualization
• 1.7. Model Details
  • 1.7.1. Commodity Flow Analysis
• 1.8. List of Secondary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. U.S. Liquid Embolic Agent Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increasing incidence of conditions such as arteriovenous malformations (AVMs), aneurysms, and hemorrhages necessitates embolization procedures
    • 3.2.1.2. Advancements in embolization technologies
    • 3.2.1.3. Increasing adoption in oncology treatments
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High cost of materials and procedures
    • 3.2.2.2. Strict regulatory approvals and compliance
  • 3.2.3. Market Opportunities Analysis
    • 3.2.3.1. Emerging applications
  • 3.2.4. Market Challenges Analysis
• 3.3. U.S. Liquid Embolic Agent Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitutes
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political & Legal Landscape
    • 3.3.2.2. Economic and Social Landscape
    • 3.3.2.3. Technological landscape

Chapter 4. U.S. Liquid Embolic Agent Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. U.S. Liquid Embolic Agent Market Product Movement Analysis
• 4.3. U.S. Liquid Embolic Agent Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
• 4.4. Ethylene Vinyl Alcohol Copolymer (EVOH)
  • 4.4.1. Ethylene Vinyl Alcohol Copolymer (EVOH) U.S. Liquid Embolic Agent Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. Cyanoacrylates
  • 4.5.1. Cyanoacrylates U.S. Liquid Embolic Agent Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5.2. N-BCA
    • 4.5.2.1. N-BCA U.S. Liquid Embolic Agent Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5.3. N-HCA
    • 4.5.3.1. N-HCA U.S. Liquid Embolic Agent Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Others
  • 4.6.1. Others U.S. Liquid Embolic Agent Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. U.S. Liquid Embolic Agent Market: Application Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. U.S. Liquid Embolic Agent Market Application Movement Analysis
• 5.3. U.S. Liquid Embolic Agent Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
• 5.4. Arteriovenous Malformations (AVM)
  • 5.4.1. Arteriovenous Malformations (AVM) U.S. Liquid Embolic Agent Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Hypervascular Tumors
  • 5.5.1. Hypervascular Tumors U.S. Liquid Embolic Agent Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Peripheral Vasculature Hemorrhage
  • 5.6.1. Peripheral Vasculature Hemorrhage U.S. Liquid Embolic Agent Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.7. Others
  • 5.7.1. Others U.S. Liquid Embolic Agent Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. U.S. Liquid Embolic Agent Market: End Use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. U.S. Liquid Embolic Agent Market End Use Movement Analysis
• 6.3. U.S. Liquid Embolic Agent Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
• 6.4. Hospitals
  • 6.4.1. Hospitals U.S. Liquid Embolic Agent Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Specialty Clinics
  • 6.5.1. Specialty Clinics U.S. Liquid Embolic Agent Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Ambulatory Surgery Centers
  • 6.6.1. Ambulatory Surgery Centers U.S. Liquid Embolic Agent Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.7. Other End Use
  • 6.7.1. Other End Use U.S. Liquid Embolic Agent Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Market Participant Categorization
• 7.2. Key Company Profiles
  • 7.2.1. Medtronic
    • 7.2.1.1. Company Overview
    • 7.2.1.2. Financial Performance
    • 7.2.1.3. Product Benchmarking
    • 7.2.1.4. Strategic Initiatives
  • 7.2.2. Terumo
    • 7.2.2.1. Company Overview
    • 7.2.2.2. Financial Performance
    • 7.2.2.3. Product Benchmarking
    • 7.2.2.4. Strategic Initiatives
  • 7.2.3. Boston Scientific Corporation
    • 7.2.3.1. Company Overview
    • 7.2.3.2. Financial Performance
    • 7.2.3.3. Product Benchmarking
    • 7.2.3.4. Strategic Initiatives
  • 7.2.4. Johnson & Johnson
    • 7.2.4.1. Company Overview
    • 7.2.4.2. Financial Performance
    • 7.2.4.3. Product Benchmarking
    • 7.2.4.4. Strategic Initiatives
  • 7.2.5. Sirtex (BlackSwan Vascular, Inc.)
    • 7.2.5.1. Company Overview
    • 7.2.5.2. Financial Performance
    • 7.2.5.3. Product Benchmarking
    • 7.2.5.4. Strategic Initiatives
  • 7.2.6. Others
    • 7.2.6.1. Company Overview
    • 7.2.6.2. Financial Performance
    • 7.2.6.3. Product Benchmarking
    • 7.2.6.4. Strategic Initiatives
• 7.3. Company Market Share Analysis, 2024
• 7.4. List of Other Key Market Players